164 related articles for article (PubMed ID: 16170191)
1. Overestimation of the prognostic significance of SUV measurement by positron emission tomography for non-small-cell lung cancer.
Atkins CD
J Clin Oncol; 2005 Sep; 23(27):6799-800; author reply 6800. PubMed ID: 16170191
[No Abstract] [Full Text] [Related]
2. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
Berghmans T; Dusart M; Paesmans M; Hossein-Foucher C; Buvat I; Castaigne C; Scherpereel A; Mascaux C; Moreau M; Roelandts M; Alard S; Meert AP; Patz EF; Lafitte JJ; Sculier JP;
J Thorac Oncol; 2008 Jan; 3(1):6-12. PubMed ID: 18166834
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of fluorodeoxyglucose uptake in non-small cell lung cancer: time for standardization and validation.
Dooms C; Vansteenkiste J
J Thorac Oncol; 2010 May; 5(5):583-4. PubMed ID: 20421763
[No Abstract] [Full Text] [Related]
4. [Non small cell lung carcinoma - evaluation of tumor heterogeneity using CT texture analysis].
Manych M
Rofo; 2012 Nov; 184(11):978. PubMed ID: 23104480
[No Abstract] [Full Text] [Related]
5. Use of anthropometric factors in 18F-FDG PET bone marrow SUVs.
Thie JA
J Nucl Med; 2006 Nov; 47(11):1901-2; author reply 1902. PubMed ID: 17079825
[No Abstract] [Full Text] [Related]
6. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
Downey RJ; Akhurst T; Gonen M; Vincent A; Bains MS; Larson S; Rusch V
J Clin Oncol; 2004 Aug; 22(16):3255-60. PubMed ID: 15310769
[TBL] [Abstract][Full Text] [Related]
7. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
[TBL] [Abstract][Full Text] [Related]
8. Lessons from the old masters: pragmatism or purity, FDG PET SUV, serum glucose and prediction of nodal status in non-small cell lung cancer.
Akhurst T
J Surg Oncol; 2006 Dec; 94(7):547-8. PubMed ID: 17111390
[No Abstract] [Full Text] [Related]
9. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.
Vansteenkiste JF
Lung Cancer; 2005 Feb; 47(2):151-3. PubMed ID: 15639713
[No Abstract] [Full Text] [Related]
11. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.
Downey RJ; Akhurst T; Gonen M; Park B; Rusch V
J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1419-27. PubMed ID: 17532932
[TBL] [Abstract][Full Text] [Related]
12. 18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer.
Giaccone G
J Natl Cancer Inst; 2007 Dec; 99(23):1741-3. PubMed ID: 18042929
[No Abstract] [Full Text] [Related]
13. [Can positron-emission tomography modify the management of non-small-cell lung cancer?].
Ninane V
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S5-7. PubMed ID: 16719146
[No Abstract] [Full Text] [Related]
14. Quantification of 18F-FDG uptake in non-small cell lung cancer: a feasible prognostic marker?
Buck AK; Glatting G; Reske SN
J Nucl Med; 2004 Aug; 45(8):1274-6. PubMed ID: 15299047
[No Abstract] [Full Text] [Related]
15. Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era.
De Pas TM; de Braud F; Catalano G; Putzu C; Veronesi G; Leo F; Solli PG; Brambilla D; Paganelli G; Spaggiari L
Ann Thorac Surg; 2007 Jan; 83(1):231-4. PubMed ID: 17184669
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
Kong FM; Frey KA; Quint LE; Ten Haken RK; Hayman JA; Kessler M; Chetty IJ; Normolle D; Eisbruch A; Lawrence TS
J Clin Oncol; 2007 Jul; 25(21):3116-23. PubMed ID: 17634490
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
[TBL] [Abstract][Full Text] [Related]
18. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.
Laking G; Price P
Thorax; 2001 Sep; 56 Suppl 2(Suppl 2):ii38-44. PubMed ID: 11514705
[No Abstract] [Full Text] [Related]
19. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.
van Baardwijk A; Dooms C; van Suylen RJ; Verbeken E; Hochstenbag M; Dehing-Oberije C; Rupa D; Pastorekova S; Stroobants S; Buell U; Lambin P; Vansteenkiste J; De Ruysscher D
Eur J Cancer; 2007 Jun; 43(9):1392-8. PubMed ID: 17512190
[TBL] [Abstract][Full Text] [Related]
20. The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers.
Bryant AS; Cerfolio RJ
J Thorac Cardiovasc Surg; 2006 Dec; 132(6):1363-8. PubMed ID: 17140957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
